Paliperidonă Teva (Paliperidone Palmitate)

After intramuscular injection, paliperidone palmitate is hydrolysed to paliperidone, which blocks dopamine D2 and serotonin 5‑HT2A receptors. This antagonism modulates neurotransmission pathways that are over‑active in psychotic conditions, thereby reducing hallucinations, delusions and mood disturbances.

The dosing regimen for paliperidone palmitate is individualized by the prescribing clinician based on the patient’s clinical status, prior oral therapy and response. The prescriber determines the injection strength, interval and any dose adjustments required.

Safety data in pregnancy and lactation are limited. Paliperidone may cross the placenta and is excreted in breast milk, so clinicians must weigh potential benefits against possible risks to the fetus or infant before prescribing.

To request Paliperidonă Teva, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Paliperidone palmitate offers a long‑acting injectable option, reducing the need for daily oral dosing compared with agents like risperidone or olanzapine. This can improve adherence but requires clinic visits for injection and carries injection‑site considerations not seen with oral formulations.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to administration, allow the vial to reach room temperature as directed by the prescribing information.

Paliperidonă Teva is given as an intramuscular injection, typically into the deltoid or gluteal muscle, by a qualified healthcare professional. The injection schedule (e.g., monthly or every three months) is set by the prescriber based on therapeutic response.

Serious adverse events include neuroleptic malignant syndrome, tardive dyskinesia, severe orthostatic hypotension, seizures, hyperglycaemia and rare blood dyscrasias. Patients should be monitored regularly for these conditions, and treatment should be stopped if they occur.

Paliperidonă Teva is contraindicated in individuals with known hypersensitivity to paliperidone or any component of the formulation, and should be used with caution in patients with uncontrolled cardiovascular disease, severe renal impairment, or a history of neuroleptic malignant syndrome.